Cooley Advises Cara Therapeutics on its Initial Public Offering

New York – February 6, 2014 – Cooley LLP announced today that it advised Cara Therapeutics, Inc. on its $55 million IPO. Cara Therapeutics, a biotechnology company focused on developing novel therapeutics to treat human diseases associated with pain and inflammation, now trades on the NASDAQ Global Stock Market under the symbol "CARA."

The Cooley corporate and securities team advising Cara was led by partner Bo Yaghmaie and included partners Darren DeStefano and Stephane Levy and associates Hosea Chang, Alexander Rea, Brandy Ellis, Steve Bielecki, Jenny Baer Tuohy, and Rachel High. Critical support for the offering was provided by partner Thomas Blinka and associate Sandhya Deo (intellectual property); partners Natasha Leskovsek and Wendy Goldstein and associate Jennifer Shanley (healthcare and life sciences regulatory); partner Dave Walsh (compensation and benefits); and partners Mike Faber and Mark Windfeld-Hansen (tax).

This offering follows Cooley's record year for capital markets work in 2013 in which the firm advised on 60 public offerings, including 23 IPOs, raising more than $8.4 billion.

About Cooley LLP

Cooley's attorneys solve legal issues for entrepreneurs, investors, financial institutions and established companies. Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and bet-the-company litigation, often where innovation meets the law.

Cooley has more than 750 lawyers across 11 offices in the United States and China.

Related Contacts
David Walsh Partner, Reston
Darren DeStefano Partner, Reston
Thomas Blinka Partner, Washington, DC
Alexander Rea Special Counsel, New York
Natasha Leskovsek Partner, Washington, DC
Mark Windfeld-Hansen Partner, Palo Alto
Stephane Levy Partner, New York
Sandhya Deo Associate, Washington, DC
Mike Faber Senior Counsel, San Francisco
Babak Yaghmaie Partner, New York
Related Practices & Industries

Capital Markets Public Companies Life Sciences